Physician profile
Alan H Burghauser
NPI 1992806608
$6,501.51
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,027 · 2020: $1,620 · 2021: $1,626 · 2022: $1,228.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,256.52 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $907.38 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $865.39 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $615.06 | 2019-2021 | |
| Philips North America LLC | $484.28 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.81 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $252.15 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $193.76 | 2019-2022 | |
| Genzyme Corporation | $176.00 | 2019-2021 | |
| United Therapeutics Corporation | $142.35 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $138.40 | 2020-2022 | |
| Mylan Specialty L.P. | $137.34 | 2019-2022 | |
| Covis Pharma Gmbh | $129.85 | 2021-2022 | |
| Advanced Respiratory, INC | $129.51 | 2019-2021 | |
| Insmed, INC. | $121.95 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $109.20 | 2020-2022 | |
| Pfizer INC. | $86.97 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $66.58 | 2022 | |
| Mallinckrodt Enterprises LLC | $50.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $40.52 | 2020-2021 | |
| Gilead Sciences, INC. | $33.46 | 2019 | |
| Electromed, INC. | $31.59 | 2019-2021 | |
| Optinose US, INC. | $27.48 | 2019-2020 | |
| Resmed Corp | $25.93 | 2019 | |
| Grifols USA, LLC | $25.81 | 2019-2020 | |
| Harmony Biosciences LLC | $25.59 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.51 | 2022 | |
| Circassia INC. | $13.34 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.29 | 2022 | |
| Merck Sharp & Dohme LLC | $11.84 | 2019 | |
| Shire North American Group INC | $11.78 | 2019 | |
| Boston Scientific Corporation | $11.09 | 2021 | |
| Amarin Pharma, INC. | $11.06 | 2021 | |
| Genentech USA, INC. | $10.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Burghauser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.